Staphylococcal SSL5 inhibits leukocyte activation by chemokines and anaphylatoxins

Blood

Volumn 113, Issue 2, 2009, Pages 328-337

  Bestebroer, Jovanka ^a   Van Kessel, Kok P M ^a   Azouagh, Hafida ^a   Walenkamp, Annemiek M ^b   Boer, Ingrid G J ^a   Romijn, Roland A ^c   Van Strijp, Jos A G ^a   De Haas, Carla J C ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c U Protein Express BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ANAPHYLATOXIN; BACTERIAL ANTIGEN; CALCIUM; CHEMOATTRACTANT; CHEMOKINE; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR4; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; CXCL1 CHEMOKINE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; G PROTEIN COUPLED RECEPTOR; GLYCOSAMINOGLYCAN; INTERLEUKIN 8; LEUKOTRIENE RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; P SELECTIN GLYCOPROTEIN LIGAND 1; RANTES; SIALYL LEWIS X ANTIGEN; STAPHYLOCOCCAL SUPERANTIGEN LIKE 5 PROTEIN; STROMAL CELL DERIVED FACTOR 1; SUPERANTIGEN; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; CHEMOKINE RECEPTOR; EXOTOXIN; GALACTOSYL (1,4) FUCOPYRANOSYL (1,3) N ACETYLGLUCOSAMINE; GALACTOSYL-(1,4)-FUCOPYRANOSYL-(1,3)-N-ACETYLGLUCOSAMINE; IMMUNOLOGIC FACTOR; MEMBRANE PROTEIN; P SELECTIN LIGAND PROTEIN; P-SELECTIN LIGAND PROTEIN; TRISACCHARIDE; VIRULENCE FACTOR;

ACTIN POLYMERIZATION; AMINO TERMINAL SEQUENCE; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; BINDING SITE; CALCIUM MOBILIZATION; CHEMOTAXIS; CONTROLLED STUDY; EMBRYO; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; LEUKOCYTE ACTIVATION; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN TARGETING; STAPHYLOCOCCUS AUREUS; TARGET CELL; CALCIUM SIGNALING; CELL LINE; IMMUNOLOGY; LEUKOCYTE ROLLING; METABOLISM; PATHOGENICITY;

ANAPHYLATOXINS; BACTERIAL PROTEINS; CALCIUM SIGNALING; CELL LINE; CHEMOKINES; EXOTOXINS; HUMANS; IMMUNOLOGIC FACTORS; LEUKOCYTE ROLLING; MEMBRANE GLYCOPROTEINS; NEUTROPHIL ACTIVATION; NEUTROPHILS; PROTEIN BINDING; RECEPTORS, CHEMOKINE; STAPHYLOCOCCUS AUREUS; TRISACCHARIDES; VIRULENCE FACTORS;

EID: 58849119618     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-04-153882     Document Type: Article

References (47)

1. Rooijakkers SH, van Kessel KP, van Strijp JA. Staphylococcal innate immune evasion. Trends Microbiol. 2005;13:596-601.
2. Postma B, Kleibeuker W, Poppelier MJ, et al. Residues 10-18 within the C5a receptor N terminus compose a binding domain for chemotaxis inhibitory protein of Staphylococcus aureus. J Biol Chem. 2005;280:2020-2027.
3. Postma B, Poppelier MJ, van Galen JC, et al. Chemotaxis inhibitory protein of Staphylococcus aureus binds specifically to the C5a and formylated peptide receptor. J Immunol. 2004;172: 6994-7001.
4. Haas PJ, de Haas CJ, Poppelier MJ, et al.The structure of the C5a receptor-blocking domain of chemotaxis inhibitory protein of Staphylococcus aureus is related to a group of immune evasive molecules. J Mol Biol. 2005;353:859-872.
5. Jongerius I, Kohl J, Pandey MK, et al. Staphylococcal complement evasion by various convertase-blocking molecules. J Exp Med. 2007;204: 2461-2471.
6. Arcus VL, Langley R, Proft T, Fraser JD, Baker EN. The Three-dimensional structure of a superantigen-like protein, SET3, from a pathogenicity island of the Staphylococcus aureus genome. J Biol Chem. 2002;277:32274-32281.
7. Langley R, Wines B, Willoughby N, Basu I, Proft T, Fraser JD. The staphylococcal superantigenlike protein 7 binds IgAand complement C5 and inhibits IgA-Fc alpha RI binding and serum killing of bacteria. J Immunol. 2005;174:2926-2933.
8. Bestebroer J, Poppelier MJ, Ulfman LH, et al. Staphylococcal superantigen-like 5 binds PSGL-1 and inhibits P-selectin-mediated neutrophil rolling. Blood. 2007;109:2936-2943.
9. Baker HM, Basu I, Chung MC, Caradoc-DaviesT Fraser JD, Baker EN. Crystal structures of the staphylococcal toxin SSL5 in complex with sialyl Lewis X reveal a conserved binding site that shares common features with viral and bacterial sialic acid binding proteins. J Mol Biol. 2007;374: 1298-1308.
10. Chung MC, Wines BD, Baker H, Langley RJ, Baker EN, Fraser JD. The crystal structure of staphylococcal superantigen-like protein 11 in complex with sialyl Lewis X reveals the mechanism for cell binding and immune inhibition. Mol Microbiol. 2007;66:1342-1355.
11. Allen SJ, Crown SE, Handel TM. Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol. 2007;25:787-820.
12. Bizzarri C, BeccariAR, Bertini R, CavicchiaMR, Giorgini S, Allegretti M. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. Pharmacol Ther. 2006;112:139-149.
13. Marx PF, Brondijk TH, Plug T, et al. Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI: a novel mechanism for enzyme auto-regulation. Blood. 2008;112:2803-2809.
14. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973;52:2745-2756.
15. Fischer DG, Pike MC, Koren HS, Snyderman R. Chemotactically responsive and nonresposive forms of a continuous human monocyte cell line. J Immunol. 1980;125:463-465.
16. Kew RR, Peng T, DiMartino SJ, et al. Undifferentiated U937 cells transfected with chemoattractant receptors: a model system to investigate chemotactic mechanisms and receptor structure/function relationships. J Leukoc Biol. 1997;61:329-337.
17. Prat C, Bestebroer J, de Haas CJ, van Strijp JA, van Kessel KP. A new staphylococcal anti-inflammatory protein that antagonizes the formyl peptide receptor-like 1. J Immunol. 2006;177:8017-8026.
18. Haas PJ, de Haas CJ, Kleibeuker W, et al. N-terminal residues of the chemotaxis inhibitory protein of Staphylococcus aureus are essential for blocking formylated peptide receptor but not C5a receptor. J Immunol. 2004;173:5704-5711.
19. Wang J, Babcock GJ, Choe H, Farzan M, Sodroski J, Gabuzda D. N-linked glycosylation in the CXCR4 N-terminus inhibits binding to HIV-1 envelope glycoproteins. Virology. 2004;324:140-150.
20. Bannert N, Craig S, Farzan M, et al. Sialylated O-glycans and sulfated tyrosines in the NH2-terminal domain of CC chemokine receptor 5 contribute to high affinity binding of chemokines. J Exp Med. 2001;194:1661-1673.
21. Weathington NM, van Houwelingen AH, Noerager BD, et al. A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat Med. 2006;12:317-323.
22. Maeda Y, Kuroki R, Haase W, Michel H, Reilander H. Comparative analysis of high-affinity ligand binding and G protein coupling of the human CXCR1 chemokine receptor and of a CXCR1-Galpha fusion protein after heterologous production in baculovirus-infected insect cells. Eur J Biochem. 2004;271:1677-1689.
23. Ludwig A, Ehlert JE, Flad HD, Brandt E. Identification of distinct surface-expressed and intracellular CXC-chemokine receptor 2 glycoforms in neutrophils: N-glycosylation is essential for maintenance of receptor surface expression. J Immunol. 2000;165:1044-1052.
24. Preobrazhensky AA, Dragan S, Kawano T, et al. Monocyte chemotactic protein-1 receptor CCR2B is a glycoprotein that has tyrosine sulfation in a conserved extracellular N-terminal region. J Immunol. 2000;165:5295-5303.
25. Gao J, Choe H, Bota D, Wright PL, Gerard C, Gerard NP. Sulfation of tyrosine 174 in the human C3a receptor is essential for binding of C3a anaphylatoxin. J Biol Chem. 2003;278:37902-37908.
26. Mery L, Boulay F. Evidence that the extracellular N-terminal domain of C5aR contains amino-acid residues crucial for C5a binding. Eur J Haematol. 1993;51:282-287.
27. Wenzel-Seifert K, Seifert R. Critical role of N-terminal N-glycosylation for proper folding of the human formyl peptide receptor. Biochem Biophys Res Commun. 2003;301:693-698.
28. Chiang N, Fierro IM, Gronert K, Serhan CN. Activation of lipoxin A(4) receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation. J Exp Med. 2000;191:1197-1208.
29. Flores RV, Hernandez-Perez MG, Aquino E, Garrad RC, Weisman GA, Gonzalez FA. Agonist-induced phosphorylation and desensitization of the P2Y2 nucleotide receptor. Mol Cell Biochem. 2005;280:35-45.
30. Sabirsh A, Bywater RP, Bristulf J, Owman C, Haeggstrom JZ. Residues from transmembrane helices 3 and 5 participate in leukotriene B4 binding to BLT1. Biochemistry. 2006;45:5733-5744.
31. Tager AM, Luster AD. BLT1 and BLT2: the leuko-triene B(4) receptors. Prostaglandins Leukot Essent Fatty Acids. 2003;69:123-134.
32. Ishii I, Izumi T, Tsukamoto H, Umeyama H, Ui M, Shimizu T. Alanine exchanges of polar amino acids in the transmembrane domains of a platelet-activating factor receptor generate both constitutively active and inactive mutants. J Biol Chem. 1997;272:7846-7854.
33. Honda Z, Ishii S, Shimizu T. Platelet-activating factor receptor. J Biochem (Tokyo). 2002;131: 773-779.
34. Mills JS, Miettinen HM, Cummings D, Jesaitis AJ. Characterization of the binding site on the formyl peptide receptor using three receptor mutants and analogs of Met-Leu-Phe and Met-Met-Trp-Leu-Leu. J Biol Chem. 2000;275:39012-39017.
35. Quehenberger O, Prossnitz ER, Cavanagh SL, Cochrane CG, Ye RD. Multiple domains of the N-formyl peptide receptor are required for high-affinity ligand binding. Construction and analysis of chimeric N-formyl peptide receptors. J Biol Chem. 1993;268:18167-18175.
36. Le Y, Ye RD, Gong W, Li J, Iribarren P, Wang JM. Identification of functional domains in the formyl peptide receptor-like 1 for agonist-induced cell chemotaxis. FEBS J. 2005;272:769-778.
37. Chen Y, Corriden R, Inoue Y, et al. ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science. 2006;314:1792-1795.
38. Hagemann IS, Narzinski KD, Floyd DH, Baranski TJ. Random mutagenesis of the complement factor 5a (C5a) receptor N terminus provides a structural constraint for C5a docking. J Biol Chem. 2006;281:36783-36792.
39. Garcia RC, Cundell DR, Tuomanen EI, Kolakowski LF Jr, Gerard C, Gerard NP. The role of N-glycosylation for functional expression of the human platelet-activating factor receptor. Glycosylation is required for efficient membrane trafficking. J Biol Chem. 1995;270:25178-25184.
40. Hicks AE, Nolan SL, Ridger VC, Hellewell PG, Norman KE. Recombinant P-selectin glycoprotein ligand-1 directly inhibits leukocyte rolling by all 3 selectins in vivo: complete inhibition of rolling is not required for anti-inflammatory effect. Blood. 2003;101:3249-3256.
41. Veerman KM, Williams MJ, Uchimura K, et al. Interaction of the selectin ligand PSGL-1 with chemokines CCL21 and CCL19 facilitates efficient homing of T cells to secondary lymphoid organs. Nat Immunol. 2007;8:532-539.
42. Hirata T, Furukawa Y, Yang BG, et al. Human P-selectin glycoprotein ligand-1 (PSGL-1) interacts with the skin-associated chemokine CCL27 via sulfated tyrosines at the PSGL-1 amino terminus. J Biol Chem. 2004;279:51775-51782.
43. Alcami A. Viral mimicry of cytokines, chemokines and their receptors. Nat Rev Immunol. 2003;3:36-50.
44. Liston A, McColl S. Subversion of the chemokine world by microbial pathogens. Bioessays. 2003; 25:478-488.
45. Pruenster M, Rot A. Throwing light on DARC. Biochem Soc Trans. 2006;34:1005-1008.
46. Culley FJ, Fadlon EJ, Kirchem A, Williams TJ, Jose PJ, Pease JE. Proteoglycans are potent modulators of the biological responses of eosinophils to chemokines. Eur J Immunol. 2003;33: 1302-1310.
47. Zabel BA, Zuniga L, Ohyama T, et al. Chemoattractants, extracellular proteases, and the integrated host defense response. Exp Hematol. 2006;34:1021-1032.